Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer

Anticancer Research

Volumn 17, Issue 2B, 1997, Pages 1373-1378

  Kim, Seung Jin ^a   Shiba, Eiichi ^a   Taguchi, Tetsuya ^a   Watanabe, Taro ^a   Tanji, Yoshio ^a   Kimoto, Yasuhiko ^a   Izukura, Masaaki ^a   Takai, Shin Ichiro ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Breast cancer; Immunohistochemistry; Prognostic factor; u PAR

Indexed keywords

CELL SURFACE RECEPTOR; MONOCLONAL ANTIBODY; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR BINDING; RECURRENCE RISK; STROMA CELL;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; RECEPTORS, CELL SURFACE;

EID: 0030889555     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Duffy MJ: The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10: 145-155, 1992.
2. Schmitt M, Janicke F and Graeff H: Tumor-associated fibrinolysis: the prognostic relevance of plasminutesogen activators uPA and tPA in human breast cancer. Blood Coagul and Fibrinol 1: 695-702, 1990.
3. Ganesh S, Sier CFM, Griffioen G, Vloedgraven HJM, Boer A, Welvaart K, van de Velde CJH, van Krieken JHJM, Verheijen JH, Lamers CBHW, and Verspaget HW: Prognostic relevance of plasminutesogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065-4071, 1994.
4. Ganesh S, Sier CFM, Heerding MM, van Krieken JHJM, Griffioen Gerrit, Welvaart K, van de Velde CJH, Verheijen JH, Lamers CBHW, and Verspaget HW: Prognostic value of the plasminutesogen activators system in patients with gastric carcinoma. Cancer 77: 1035-1043, 1996.
5. Moller LB: Structure and function of the urokinase receptor. Blood Coagul Fibrinol 4: 293-303, 1993.
6. Duffy MJ: Urokinase-type plasminutesogen activator and malignancy. Fibrinolysis 7: 295-302, 1993.
7. Dano K, Behrendt N, Brunner N, Ellis V, and Pyke C: The urokinase receptor. Protein structure and role in plasminutesogen activator and cancer invasion. Fibrinolysis 8: 189-203, 1994.
8. Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, and Nenci GG: Combined overexpression of urokinase, urokinase receptor, and plasminutesogen activator inhibitor-1 is associated with breast cancer progression. Cancer 77: 1079-1088, 1996.
9. Pyke C, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Kirkeby L, and Dano K: Immunohistochemical detection of the receptor for urokinase plasminutesogen activator in human colon cancer. Histopathology 24: 131-138, 1994.
10. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch K-W, Loehrs U, and Schildberg FW: Tumor-associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 13: 2084-2093, 1995.
11. Vecchio SD, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, and Salvatore M: Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradíography: comparison with urokinase levels. Cancer Res 53: 3198-3206, 1993.
12. Pepper MS, and Montesano R: Proteolytic balance and capillary morphogenesis. Cell Diff Develop 32: 319-328, 1990.
13. Suehiro T, Shimada M, Matsumata T, Taketomi A, Yamamoto K, and Sugimachi K: Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology 21: 1285-1290, 1995.
14. Ethier SP: Growth factor synthesis and human breast cancer progression. J Natl Cancer I 87: 964-973, 1995.
15. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, and Cheresh DA: Definition of two angiogenic pathways by distinct α v integrins. Science 270: 1500-1502, 1995.